Bharat Biotech Concluded Phase III Clinical Development

Bharat Biotech International said that controlled clinical studies on participants showed that BBV154 (the intranasal vaccination) was safe, well-tolerated, and immunogenic on August 15. A pre-fusion stabilized spike protein is present in the recombinant replication-deficient adenovirus vector vaccine known as BBV154. Phase I and II clinical studies conducted previously on this vaccine candidate had positive outcomes. BBV154 has been created particularly to enable intranasal administration.